This is designed to test how well the drug or treatment works as well as to continue safety assessments on a larger group of patients (20-300). When the development process for a new drug fails, this usually occurs during Phase II trials when the drug is discovered not to work as planned, or to have toxic effects. Only one-third of experimental drugs successfully complete both phase I and phase II studies.